Alexieva-Figusch J, van Gilse H A, Hop W C, Phoa C H, Blonk-van der Wijst J, Treurniet R E
Cancer. 1980 Dec 1;46(11):2369-72. doi: 10.1002/1097-0142(19801201)46:11<2369::aid-cncr2820461111>3.0.co;2-3.
Progestin megestrol acetate treatment of 160 postmenopausal women with progressive metastatic breast cancer is evaluated. Objective remission was found in 48 patients (30%) and stabilization of disease occurred in 58 (36%) cases. In each of these response categories, the median time interval before subsequent progression took place was nine months. Patients with a postmenopausal age of more than five years showed a significantly higher remission rate than did younger patients. In addition, great differences in remission rates were apparent between groups of patients classified according to dominant sites and separate sites of lesions. The length of disease-free interval did not prove to be of great importance in predicting the remission. No great difference in remission rates were found between patients treated with megestrol acetate as the first hormonal treatment and those previously treated with hormones. Side effects were negligible; a moderate weight increase without demonstrated fluid retention was found during therapy in 10% of the cases. Toxicity was not encountered. Megestrol acetate therapy may be the first choice of treatment in late postmenopausal patients with soft tissue and lung metastases.
对160例患有进行性转移性乳腺癌的绝经后女性采用醋酸甲地孕酮进行孕激素治疗并进行评估。48例患者（30%）出现客观缓解，58例（36%）病情稳定。在这些反应类别中，后续病情进展前的中位时间间隔均为9个月。绝经年龄超过5年的患者缓解率明显高于年轻患者。此外，根据主要部位和病变的不同部位分类的患者组之间缓解率存在显著差异。无病间期的长短在预测缓解方面并不十分重要。作为首次激素治疗接受醋酸甲地孕酮治疗的患者与先前接受过激素治疗的患者之间缓解率无显著差异。副作用可忽略不计；10%的病例在治疗期间体重适度增加，但未显示有液体潴留。未发现毒性反应。醋酸甲地孕酮治疗可能是晚期绝经后伴有软组织和肺转移患者的首选治疗方法。
